Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of SCH 503034 With PegIntron and Ribavirin in Untreated Genotype 1 Chronic Hepatitis C
2006-002543-92Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of boceprevir in hepatitis C virus infection, sponsored by Merck & Co. Primary endpoint: Sustained virologic response at follow-up week 24. Started Nov 2006; status: completed.
02
Drugs
boceprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2006-002543-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002543-92.